Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Stock Competitors & Peer Comparison
See RXRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RXRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RXRX | $3.56 | +9.54% | 1.9B | -3.42 | -$1.04 | N/A |
| VRTX | $552.85 | +0.96% | 140.3B | 29.05 | $19.03 | N/A |
| REGN | $833.56 | +0.61% | 85.9B | 18.27 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,019.49 | +0.83% | 63.4B | 92.01 | $11.08 | N/A |
| MRNA | $158.83 | +14.36% | 63B | -19.49 | -$8.15 | N/A |
| RVMDW | $11.98 | -0.42% | 47.4B | -1.67 | -$7.21 | N/A |
| RVMD | $211.38 | -0.09% | 44.9B | -23.97 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $376.37 | +1.18% | 40.2B | 66.26 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
RXRX vs VRTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, VRTX has a market cap of 140.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while VRTX trades at $552.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas VRTX's P/E ratio is 29.05. In terms of profitability, RXRX's ROE is -0.50%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, RXRX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
RXRX vs REGN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, REGN has a market cap of 85.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while REGN trades at $833.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas REGN's P/E ratio is 18.27. In terms of profitability, RXRX's ROE is -0.50%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RXRX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
RXRX vs VRNA Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RXRX's ROE is -0.50%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RXRX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
RXRX vs ARGX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ARGX has a market cap of 63.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ARGX trades at $1,019.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ARGX's P/E ratio is 92.01. In terms of profitability, RXRX's ROE is -0.50%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, RXRX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
RXRX vs MRNA Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MRNA has a market cap of 63B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MRNA trades at $158.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MRNA's P/E ratio is -19.49. In terms of profitability, RXRX's ROE is -0.50%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, RXRX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for RXRX.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
RXRX vs RVMDW Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RVMDW has a market cap of 47.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RVMDW trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RVMDW's P/E ratio is -1.67. In terms of profitability, RXRX's ROE is -0.50%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, RXRX is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
RXRX vs RVMD Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RVMD has a market cap of 44.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RVMD trades at $211.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RVMD's P/E ratio is -23.97. In terms of profitability, RXRX's ROE is -0.50%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, RXRX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
RXRX vs SGEN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RXRX's ROE is -0.50%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RXRX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
RXRX vs ONC Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ONC has a market cap of 40.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ONC trades at $376.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ONC's P/E ratio is 66.26. In terms of profitability, RXRX's ROE is -0.50%, compared to ONC's ROE of +0.14%. Regarding short-term risk, RXRX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
RXRX vs ALNY Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ALNY has a market cap of 32.1B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ALNY trades at $240.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ALNY's P/E ratio is 43.26. In terms of profitability, RXRX's ROE is -0.50%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, RXRX is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
RXRX vs BNTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, BNTX has a market cap of 28.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while BNTX trades at $114.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas BNTX's P/E ratio is -14.79. In terms of profitability, RXRX's ROE is -0.50%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, RXRX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
RXRX vs INSM Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, INSM has a market cap of 26.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while INSM trades at $123.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas INSM's P/E ratio is -30.14. In terms of profitability, RXRX's ROE is -0.50%, compared to INSM's ROE of -1.11%. Regarding short-term risk, RXRX is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
RXRX vs ROIV Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ROIV trades at $36.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ROIV's P/E ratio is -34.70. In terms of profitability, RXRX's ROE is -0.50%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, RXRX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
RXRX vs INCY Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, INCY has a market cap of 26.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while INCY trades at $129.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas INCY's P/E ratio is 17.44. In terms of profitability, RXRX's ROE is -0.50%, compared to INCY's ROE of +0.30%. Regarding short-term risk, RXRX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
RXRX vs UTHR Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while UTHR trades at $518.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas UTHR's P/E ratio is 18.55. In terms of profitability, RXRX's ROE is -0.50%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, RXRX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
RXRX vs GMAB Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, GMAB has a market cap of 21.1B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while GMAB trades at $34.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas GMAB's P/E ratio is 25.89. In terms of profitability, RXRX's ROE is -0.50%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, RXRX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
RXRX vs BGNE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RXRX's ROE is -0.50%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, RXRX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
RXRX vs DNA-WT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RXRX's ROE is -0.50%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, RXRX is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
RXRX vs JAZZ Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, JAZZ has a market cap of 16.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while JAZZ trades at $260.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas JAZZ's P/E ratio is 9.70. In terms of profitability, RXRX's ROE is -0.50%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, RXRX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
RXRX vs BBIO Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while BBIO trades at $80.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas BBIO's P/E ratio is -21.50. In terms of profitability, RXRX's ROE is -0.50%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, RXRX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
RXRX vs ASND Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ASND trades at $252.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ASND's P/E ratio is -104.54. In terms of profitability, RXRX's ROE is -0.50%, compared to ASND's ROE of +1.90%. Regarding short-term risk, RXRX is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
RXRX vs NBIX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while NBIX trades at $153.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas NBIX's P/E ratio is 22.16. In terms of profitability, RXRX's ROE is -0.50%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, RXRX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
RXRX vs EXEL Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, EXEL has a market cap of 14.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while EXEL trades at $56.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas EXEL's P/E ratio is 16.21. In terms of profitability, RXRX's ROE is -0.50%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, RXRX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check EXEL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
RXRX vs HALO Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, HALO has a market cap of 13B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while HALO trades at $109.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas HALO's P/E ratio is 20.40. In terms of profitability, RXRX's ROE is -0.50%, compared to HALO's ROE of +1.81%. Regarding short-term risk, RXRX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
RXRX vs BMRN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, BMRN has a market cap of 12.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while BMRN trades at $66.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas BMRN's P/E ratio is 31.79. In terms of profitability, RXRX's ROE is -0.50%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, RXRX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
RXRX vs KRTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RXRX's ROE is -0.50%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RXRX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
RXRX vs ARWR Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ARWR has a market cap of 12.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ARWR trades at $88.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ARWR's P/E ratio is -39.50. In terms of profitability, RXRX's ROE is -0.50%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, RXRX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
RXRX vs MDGL Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MDGL trades at $512.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MDGL's P/E ratio is -40.01. In terms of profitability, RXRX's ROE is -0.50%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, RXRX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
RXRX vs TECH Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while TECH trades at $72.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas TECH's P/E ratio is 37.28. In terms of profitability, RXRX's ROE is -0.50%, compared to TECH's ROE of +0.09%. Regarding short-term risk, RXRX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
RXRX vs RNAM Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RXRX's ROE is -0.50%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RXRX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RNAM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
RXRX vs SMMT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, SMMT has a market cap of 10.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while SMMT trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas SMMT's P/E ratio is -11.93. In terms of profitability, RXRX's ROE is -0.50%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, RXRX is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check SMMT's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
RXRX vs AXSM Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while AXSM trades at $205.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas AXSM's P/E ratio is -53.65. In terms of profitability, RXRX's ROE is -0.50%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, RXRX is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check AXSM's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
RXRX vs IONS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, IONS has a market cap of 10.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while IONS trades at $63.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas IONS's P/E ratio is -36.96. In terms of profitability, RXRX's ROE is -0.50%, compared to IONS's ROE of -1.11%. Regarding short-term risk, RXRX is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check IONS's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
RXRX vs KRYS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, KRYS has a market cap of 10.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while KRYS trades at $356.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas KRYS's P/E ratio is 44.64. In terms of profitability, RXRX's ROE is -0.50%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RXRX is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
RXRX vs KYMR Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, KYMR has a market cap of 10.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while KYMR trades at $126.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas KYMR's P/E ratio is -39.57. In terms of profitability, RXRX's ROE is -0.50%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, RXRX is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
RXRX vs PRAX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while PRAX trades at $368.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas PRAX's P/E ratio is -28.46. In terms of profitability, RXRX's ROE is -0.50%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, RXRX is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
RXRX vs PTGX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, PTGX has a market cap of 9.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while PTGX trades at $150.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas PTGX's P/E ratio is 146.20. In terms of profitability, RXRX's ROE is -0.50%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, RXRX is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
RXRX vs CYTK Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CYTK trades at $77.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CYTK's P/E ratio is -10.73. In terms of profitability, RXRX's ROE is -0.50%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, RXRX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
RXRX vs RXDX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RXRX's ROE is -0.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
RXRX vs SYRE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, SYRE has a market cap of 9.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while SYRE trades at $107.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas SYRE's P/E ratio is -55.06. In terms of profitability, RXRX's ROE is -0.50%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, RXRX is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check SYRE's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
RXRX vs NUVL Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas NUVL's P/E ratio is -21.79. In terms of profitability, RXRX's ROE is -0.50%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RXRX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
RXRX vs CRNX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CRNX trades at $84.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CRNX's P/E ratio is -16.84. In terms of profitability, RXRX's ROE is -0.50%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RXRX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CRNX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
RXRX vs IMVT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, IMVT has a market cap of 9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while IMVT trades at $43.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas IMVT's P/E ratio is -15.43. In terms of profitability, RXRX's ROE is -0.50%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, RXRX is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
RXRX vs PCVX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while PCVX trades at $61.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas PCVX's P/E ratio is -8.01. In terms of profitability, RXRX's ROE is -0.50%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, RXRX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
RXRX vs IMGN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RXRX's ROE is -0.50%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RXRX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
RXRX vs ABVX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ABVX trades at $117.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ABVX's P/E ratio is -61.82. In terms of profitability, RXRX's ROE is -0.50%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RXRX is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ABVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
RXRX vs IBRX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while IBRX trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas IBRX's P/E ratio is -8.44. In terms of profitability, RXRX's ROE is -0.50%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, RXRX is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
RXRX vs TGTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while TGTX trades at $55.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas TGTX's P/E ratio is 20.07. In terms of profitability, RXRX's ROE is -0.50%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, RXRX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
RXRX vs BPMC Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RXRX's ROE is -0.50%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
RXRX vs APGE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while APGE trades at $134.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas APGE's P/E ratio is -31.14. In terms of profitability, RXRX's ROE is -0.50%, compared to APGE's ROE of -0.30%. Regarding short-term risk, RXRX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
RXRX vs ALKS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ALKS trades at $49.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ALKS's P/E ratio is 51.80. In terms of profitability, RXRX's ROE is -0.50%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, RXRX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
RXRX vs CERE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CERE's P/E ratio is -16.47. In terms of profitability, RXRX's ROE is -0.50%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RXRX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CERE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
RXRX vs CAI Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CAI has a market cap of 7.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CAI trades at $28.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CAI's P/E ratio is 78.70. In terms of profitability, RXRX's ROE is -0.50%, compared to CAI's ROE of +0.19%. Regarding short-term risk, RXRX is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
RXRX vs RYTM Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RYTM trades at $113.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RYTM's P/E ratio is -36.45. In terms of profitability, RXRX's ROE is -0.50%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, RXRX is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
RXRX vs MTSR Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RXRX's ROE is -0.50%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RXRX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check MTSR's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
RXRX vs SRRK Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, SRRK has a market cap of 7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while SRRK trades at $58.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas SRRK's P/E ratio is -16.88. In terms of profitability, RXRX's ROE is -0.50%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, RXRX is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
RXRX vs CGON Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CGON has a market cap of 7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CGON trades at $78.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CGON's P/E ratio is -29.35. In terms of profitability, RXRX's ROE is -0.50%, compared to CGON's ROE of -0.25%. Regarding short-term risk, RXRX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
RXRX vs MRUS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RXRX's ROE is -0.50%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RXRX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
RXRX vs ACLX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RXRX's ROE is -0.50%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RXRX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
RXRX vs RETA Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RETA's P/E ratio is -66.29. In terms of profitability, RXRX's ROE is -0.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RXRX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
RXRX vs BLTE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while BLTE trades at $161.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas BLTE's P/E ratio is -86.46. In terms of profitability, RXRX's ROE is -0.50%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, RXRX is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check BLTE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
RXRX vs COGT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while COGT trades at $36.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas COGT's P/E ratio is -17.44. In terms of profitability, RXRX's ROE is -0.50%, compared to COGT's ROE of -0.73%. Regarding short-term risk, RXRX is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check COGT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
RXRX vs DNTH Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, DNTH has a market cap of 6.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while DNTH trades at $112.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas DNTH's P/E ratio is -27.01. In terms of profitability, RXRX's ROE is -0.50%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, RXRX is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check DNTH's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
RXRX vs CNTA Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RXRX's ROE is -0.50%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RXRX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
RXRX vs TVTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while TVTX trades at $67.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas TVTX's P/E ratio is -148.91. In terms of profitability, RXRX's ROE is -0.50%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, RXRX is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check TVTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
RXRX vs ERAS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ERAS has a market cap of 6.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ERAS trades at $17.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ERAS's P/E ratio is -19.10. In terms of profitability, RXRX's ROE is -0.50%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, RXRX is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
RXRX vs ORKA Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ORKA has a market cap of 6.1B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ORKA trades at $101.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ORKA's P/E ratio is -52.48. In terms of profitability, RXRX's ROE is -0.50%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, RXRX is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ORKA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
RXRX vs PTCT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while PTCT trades at $73.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas PTCT's P/E ratio is -31.53. In terms of profitability, RXRX's ROE is -0.50%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, RXRX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
RXRX vs MIRM Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MIRM trades at $98.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MIRM's P/E ratio is -6.74. In terms of profitability, RXRX's ROE is -0.50%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, RXRX is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
RXRX vs DFTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, DFTX has a market cap of 5.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while DFTX trades at $44.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas DFTX's P/E ratio is N/A. In terms of profitability, RXRX's ROE is -0.50%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, RXRX is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check DFTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
RXRX vs CRSP Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CRSP has a market cap of 5.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CRSP trades at $60.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CRSP's P/E ratio is -12.79. In terms of profitability, RXRX's ROE is -0.50%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, RXRX is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CRSP's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
RXRX vs XENE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while XENE trades at $60.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas XENE's P/E ratio is -12.86. In terms of profitability, RXRX's ROE is -0.50%, compared to XENE's ROE of -0.44%. Regarding short-term risk, RXRX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
RXRX vs LGND Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while LGND trades at $281.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas LGND's P/E ratio is 30.92. In terms of profitability, RXRX's ROE is -0.50%, compared to LGND's ROE of +0.20%. Regarding short-term risk, RXRX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
RXRX vs CDTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RXRX's ROE is -0.50%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RXRX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
RXRX vs ABCM Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RXRX's ROE is -0.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RXRX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
RXRX vs ISEE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RXRX's ROE is -0.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RXRX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
RXRX vs APLS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas APLS's P/E ratio is 38.35. In terms of profitability, RXRX's ROE is -0.50%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RXRX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
RXRX vs ACAD Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ACAD has a market cap of 5.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ACAD trades at $30.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ACAD's P/E ratio is 13.77. In terms of profitability, RXRX's ROE is -0.50%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, RXRX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
RXRX vs DYN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while DYN trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas DYN's P/E ratio is -8.18. In terms of profitability, RXRX's ROE is -0.50%, compared to DYN's ROE of -0.64%. Regarding short-term risk, RXRX is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
RXRX vs TERN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas TERN's P/E ratio is -51.41. In terms of profitability, RXRX's ROE is -0.50%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RXRX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
RXRX vs EWTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while EWTX trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas EWTX's P/E ratio is -23.90. In terms of profitability, RXRX's ROE is -0.50%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, RXRX is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
RXRX vs PBLS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while PBLS trades at $39.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas PBLS's P/E ratio is -44.58. In terms of profitability, RXRX's ROE is -0.50%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, RXRX is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
RXRX vs FOLD Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RXRX's ROE is -0.50%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RXRX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check FOLD's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
RXRX vs RLAY Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RLAY trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RLAY's P/E ratio is -13.10. In terms of profitability, RXRX's ROE is -0.50%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, RXRX is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RLAY's competition here
Celcuity Inc. (NASDAQ: CELC)
RXRX vs CELC Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while CELC trades at $92.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas CELC's P/E ratio is -21.46. In terms of profitability, RXRX's ROE is -0.50%, compared to CELC's ROE of -3.51%. Regarding short-term risk, RXRX is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check CELC's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
RXRX vs AKRO Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RXRX's ROE is -0.50%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RXRX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
RXRX vs ALPN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RXRX's ROE is -0.50%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RXRX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
RXRX vs ELVN Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ELVN trades at $61.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ELVN's P/E ratio is -36.53. In terms of profitability, RXRX's ROE is -0.50%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, RXRX is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ELVN's competition here
Veradermics, Incorporated (NYSE: MANE)
RXRX vs MANE Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MANE trades at $102.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MANE's P/E ratio is -32.54. In terms of profitability, RXRX's ROE is -0.50%, compared to MANE's ROE of -0.29%. Regarding short-term risk, RXRX is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
RXRX vs OPT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas OPT's P/E ratio is -1.52. In terms of profitability, RXRX's ROE is -0.50%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RXRX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
RXRX vs PRTC Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas PRTC's P/E ratio is -3.78. In terms of profitability, RXRX's ROE is -0.50%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, RXRX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check PRTC's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
RXRX vs ADPT Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while ADPT trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas ADPT's P/E ratio is -64.02. In terms of profitability, RXRX's ROE is -0.50%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, RXRX is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check ADPT's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
RXRX vs AMLX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, AMLX has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while AMLX trades at $37.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas AMLX's P/E ratio is -24.97. In terms of profitability, RXRX's ROE is -0.50%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, RXRX is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check AMLX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
RXRX vs MRTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RXRX's ROE is -0.50%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RXRX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check MRTX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
RXRX vs IDYA Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, IDYA has a market cap of 4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while IDYA trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas IDYA's P/E ratio is -21.90. In terms of profitability, RXRX's ROE is -0.50%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, RXRX is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check IDYA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
RXRX vs TNGX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while TNGX trades at $24.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas TNGX's P/E ratio is -29.84. In terms of profitability, RXRX's ROE is -0.50%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, RXRX is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check TNGX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
RXRX vs VKTX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while VKTX trades at $34.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas VKTX's P/E ratio is -7.33. In terms of profitability, RXRX's ROE is -0.50%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, RXRX is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check VKTX's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
RXRX vs RCUS Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, RCUS has a market cap of 4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while RCUS trades at $31.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas RCUS's P/E ratio is -8.09. In terms of profitability, RXRX's ROE is -0.50%, compared to RCUS's ROE of -0.88%. Regarding short-term risk, RXRX is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check RCUS's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
RXRX vs TLX Comparison August 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 1.9B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, RXRX is priced at $3.56 on the NASDAQ, while TLX trades at $11.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -3.42, whereas TLX's P/E ratio is 122.03. In terms of profitability, RXRX's ROE is -0.50%, compared to TLX's ROE of +0.07%. Regarding short-term risk, RXRX is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for RXRX.Check TLX's competition here